These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 23706539)

  • 1. Can 4-aminopyridine modulate dysfunctional gait networks in Parkinson's disease?
    Luca CC; Singer C
    Parkinsonism Relat Disord; 2013 Sep; 19(9):777-82. PubMed ID: 23706539
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dalfampridine in Parkinson's disease related gait dysfunction: A randomized double blind trial.
    Luca CC; Nadayil G; Dong C; Nahab FB; Field-Fote E; Singer C
    J Neurol Sci; 2017 Aug; 379():7-11. PubMed ID: 28716283
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Significant effects of 4-aminopyridine and tetraethylammonium in the treatment of 6-hydroxydopamine-induced Parkinson's disease.
    Haghdoost-Yazdi H; Faraji A; Fraidouni N; Movahedi M; Hadibeygi E; Vaezi F
    Behav Brain Res; 2011 Sep; 223(1):70-4. PubMed ID: 21540059
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potassium channel blocker 4-aminopyridine is effective in interictal cerebellar symptoms in episodic ataxia type 2--a video case report.
    Löhle M; Schrempf W; Wolz M; Reichmann H; Storch A
    Mov Disord; 2008 Jul; 23(9):1314-6. PubMed ID: 18442126
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 4-Aminopyridine ameliorates mobility but not disease course in an animal model of multiple sclerosis.
    Göbel K; Wedell JH; Herrmann AM; Wachsmuth L; Pankratz S; Bittner S; Budde T; Kleinschnitz C; Faber C; Wiendl H; Meuth SG
    Exp Neurol; 2013 Oct; 248():62-71. PubMed ID: 23748135
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potassium channel antagonists 4-aminopyridine and the T-butyl carbamate derivative of 4-aminopyridine improve hind limb function in chronically non-ambulatory dogs; a blinded, placebo-controlled trial.
    Lim JH; Muguet-Chanoit AC; Smith DT; Laber E; Olby NJ
    PLoS One; 2014; 9(12):e116139. PubMed ID: 25551385
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dopaminergic and non-dopaminergic pharmacological hypotheses for gait disorders in Parkinson's disease.
    Devos D; Defebvre L; Bordet R
    Fundam Clin Pharmacol; 2010 Aug; 24(4):407-21. PubMed ID: 20163480
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of nigral stimulation on locomotion and postural stability in patients with Parkinson's disease.
    Chastan N; Westby GW; Yelnik J; Bardinet E; Do MC; Agid Y; Welter ML
    Brain; 2009 Jan; 132(Pt 1):172-84. PubMed ID: 19001482
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dopaminergic modulation of timing control and variability in the gait of Parkinson's disease.
    Almeida QJ; Frank JS; Roy EA; Patla AE; Jog MS
    Mov Disord; 2007 Sep; 22(12):1735-42. PubMed ID: 17557356
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 4-aminopyridine improves freezing of gait in Parkinson's disease.
    Luca CC; Singer C
    J Neurol; 2013 Oct; 260(10):2662-4. PubMed ID: 23989346
    [No Abstract]   [Full Text] [Related]  

  • 11. Step initiation in Parkinson's disease: influence of levodopa and external sensory triggers.
    Burleigh-Jacobs A; Horak FB; Nutt JG; Obeso JA
    Mov Disord; 1997 Mar; 12(2):206-15. PubMed ID: 9087979
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pathophysiology of freezing of gait and some possible treatments for it.
    Sarbaz Y; Gharibzadeh S; Towhidkhah F
    Med Hypotheses; 2012 Feb; 78(2):258-61. PubMed ID: 22115695
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Imbalance and gait impairment in Parkinson's disease: discussing postural instability and ataxia.
    Camargo CHF; Ferreira-Peruzzo SA; Ribas DIR; Franklin GL; Teive HAG
    Neurol Sci; 2024 Apr; 45(4):1377-1388. PubMed ID: 37985635
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Gait disorders in Parkinson's disease: and pathophysiological approaches].
    Moreau C; Cantiniaux S; Delval A; Defebvre L; Azulay JP
    Rev Neurol (Paris); 2010 Feb; 166(2):158-67. PubMed ID: 19616816
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The therapeutic potential of neurotrophic factors in the treatment of Parkinson's disease.
    Lindsay RM; Altar CA; Cedarbaum JM; Hyman C; Wiegand SJ
    Exp Neurol; 1993 Nov; 124(1):103-18. PubMed ID: 8282068
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Functional imaging of cognition in Parkinson's disease.
    Carbon M; Marié RM
    Curr Opin Neurol; 2003 Aug; 16(4):475-80. PubMed ID: 12869806
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fampridine-SR for multiple sclerosis and spinal cord injury.
    Hayes KC
    Expert Rev Neurother; 2007 May; 7(5):453-61. PubMed ID: 17492896
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Involvement of specific executive functions in mobility in Parkinson's disease.
    Smulders K; van Nimwegen M; Munneke M; Bloem BR; Kessels RP; Esselink RA
    Parkinsonism Relat Disord; 2013 Jan; 19(1):126-8. PubMed ID: 22771282
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gait and balance disorders in Parkinson's disease: impaired active braking of the fall of centre of gravity.
    Chastan N; Do MC; Bonneville F; Torny F; Bloch F; Westby GW; Dormont D; Agid Y; Welter ML
    Mov Disord; 2009 Jan; 24(2):188-95. PubMed ID: 18973252
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical overview of dalfampridine: an agent with a novel mechanism of action to help with gait disturbances.
    Egeberg MD; Oh CY; Bainbridge JL
    Clin Ther; 2012 Nov; 34(11):2185-94. PubMed ID: 23123001
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.